No price history available.
Key financial summary
Financials in THB| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | THBm | 1,611 | 1,015 | 537 | 678 | 645 | 609 | N/A | N/A |
| Operating profit | THBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | THBm | 141 | 233 | -345 | 7 | -159 | 60 | N/A | N/A |
| EPS reported | THB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | THB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | THB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | THB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | THBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | THBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | THBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | THB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | THB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in THB| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
DOD Biotech Public Company Limited, together with its subsidiaries, manufactures and distributes dietary supplements in Thailand. It offers dietary supplements for beauty and health in various forms comprising capsules, gels, jellies, powder, shot drinks, soft gels, tablets, probiotics, gummies, and direct-to-mouth. The company also provides food supplements and health drinks. In addition, it offers advisory, trading, and supplementary services; and research and development, design, FDA and HALAL registration, and consulting services. DOD Biotech Public Company Limited was incorporated in 2011 and is based in Mueang Samut Sakhon, Thailand.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
DOD Biotech Public Co., Ltd. (DOD.BK)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
DOD Biotech Public Company Limited, together with its subsidiaries, manufactures and distributes dietary supplements in Thailand. It offers dietary supplements for beauty and health in various forms comprising capsules, gels, jellies, powder, shot drinks, soft gels, tablets, probiotics, gummies, and direct-to-mouth. The company also provides food supplements and health drinks. In addition, it offers advisory, trading, and supplementary services; and research and development, design, FDA and HALAL registration, and consulting services. DOD Biotech Public Company Limited was incorporated in 2011 and is based in Mueang Samut Sakhon, Thailand.